Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and
GlobeNewswireApr 25 16:30 ET
Ultragenyx Pharma Is Maintained at Buy by TD Cowen
Ultragenyx Pharma Is Maintained at Buy by TD Cowen
Dow JonesApr 24 13:33 ET
Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen
Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen
Dow JonesApr 24 13:33 ET
Express News | Ultragenyx Pharmaceutical Inc : TD Cowen Raises Target Price to $61 From $59
Moomoo 24/7Apr 24 07:24 ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
TipRanksApr 23 08:40 ET
Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanksApr 22 08:29 ET
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table summarizes their rec
BenzingaApr 22 08:00 ET
Express News | Ultragenyx Pharmaceutical Inc : RBC Initiates Coverage With Outperform Rating; Price Target $77: RBC Initiates Coverage With Outperform Rating; Price Target $77
Moomoo 24/7Apr 22 02:08 ET
Ultragenyx Pharmaceutical(RARE.US) Officer Sells US$6,262.2 in Common Stock
$Ultragenyx Pharmaceutical(RARE.US)$ Officer Crombez Eric sold 142 shares of common stock on Apr 18, 2024 at an average price of $44.1 for a total value of $6,262.2.Source: Announcement What is statem
moomoo NewsApr 19 17:19 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare
GlobeNewswireApr 19 16:30 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanksApr 18 06:10 ET
Buy Rating on Ultragenyx Pharmaceutical Bolstered by GTX-102's Promise and Positive Valuation Outlook
TipRanksApr 18 00:26 ET
Investors Aren't Buying Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) price-to-sales (or "P/S") ratio of 8x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half o
Simply Wall StApr 17 12:27 ET
As More Rare Disease Therapies Launch, Their Prices Are Rising
Seeking AlphaApr 16 12:22 ET
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $48 price target.
BenzingaApr 16 10:20 ET
Ultragenyx Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 9.46% Wedbush → $48 Reiterates Neutral → Neutral 04/05/2024 144.01% Cantor Fitzgerald → $107 Re
BenzingaApr 16 10:19 ET
Rare disease giant Ultragenyx (RARE.US) antisense oligonucleotide therapy advances to phase 3 clinical sword-finger angel syndrome
Ultragenyx Pharmaceutical (RARE.US) announced the latest data obtained in a phase 1/2 clinical trial of GTX-102, an investigational therapy used to treat Angelman syndrome (Angelman syndrome).
Zhitong FinanceApr 16 09:10 ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)
TipRanksApr 16 08:11 ET
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE)
TipRanksApr 16 08:00 ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)
TipRanksApr 15 20:40 ET
No Data
No Data